New research showed that tirzepatide, the compound in Zepbound, improved symptoms of obstructive sleep apnea.
Vous n'êtes pas connecté
Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing disorder and expects regulators to make a decision as early as the end of the year. If cleared by the Food and Drug Administration, the company plans to launch Zepbound for so-called obstructive […]
New research showed that tirzepatide, the compound in Zepbound, improved symptoms of obstructive sleep apnea.
Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales...
Researchers at University of California San Diego School of Medicine and international collaborators have led a worldwide, advanced study...
In recent research led by the University of California San Diego School of Medicine, scientists have found a new potential treatment for obstructive...
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the...
The Subject Expert Committee (SEC), which advises the national drug regulator on drugs and trials approval matters, has recommended grant of...
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the...
Research raises possibility that tirzepatide could become first pharmaceutical treatment for the sleeping disorder
INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL...
Cleveland Clinic study reveals that weight loss surgery significantly reduces the risk of heart complications by 42% and the risk of death by 37% in...